US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NYSE
Merck and Co Inc (MRK)
Merck and Co Inc (MRK) ニュース

MRK

Merck (MRK)

Merck and Co Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:MRK

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	05 : 39	Edgar (US Regulatory)	Form CERT - Certification by an exchange approving securities for listing	NYSE:MRK	Merck and Co Inc
2024/05/31	05 : 28	Edgar (US Regulatory)	Form 8-A12B - Registration of securities [Section 12(b)]	NYSE:MRK	Merck and Co Inc
2024/05/31	05 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:MRK	Merck and Co Inc
2024/05/29	22 : 10	IH Market News	Rising Treasury Yields May Weigh On Wall Street	NYSE:MRK	Merck and Co Inc
2024/05/29	20 : 34	IH Market News	Robinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More News	NYSE:MRK	Merck and Co Inc
2024/05/29	20 : 15	Business Wire	FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	NYSE:MRK	Merck and Co Inc
2024/05/29	19 : 45	Business Wire	Merck to Acquire EyeBio	NYSE:MRK	Merck and Co Inc
2024/05/29	05 : 44	IH Market News	Nasdaq Climbs To Another Record Closing High But Dow Sees Further Downside	NYSE:MRK	Merck and Co Inc
2024/05/29	05 : 31	Edgar (US Regulatory)	Form SD - Specialized disclosure report	NYSE:MRK	Merck and Co Inc
2024/05/29	04 : 12	Business Wire	Merck Announces Third-Quarter 2024 Dividend	NYSE:MRK	Merck and Co Inc
2024/05/28	19 : 45	Business Wire	Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)	NYSE:MRK	Merck and Co Inc
2024/05/20	19 : 28	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:MRK	Merck and Co Inc
2024/05/17	05 : 15	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NYSE:MRK	Merck and Co Inc
2024/05/16	00 : 31	Edgar (US Regulatory)	Form POSASR - Post-effective Amendment to an automatic shelf registration statement	NYSE:MRK	Merck and Co Inc
2024/05/15	19 : 45	Business Wire	Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline	NYSE:MRK	Merck and Co Inc
2024/05/13	19 : 45	Business Wire	Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma	NYSE:MRK	Merck and Co Inc
2024/05/09	20 : 05	PR Newswire (Canada)	Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatique	NYSE:MRK	Merck and Co Inc
2024/05/09	20 : 05	PR Newswire (Canada)	Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy	NYSE:MRK	Merck and Co Inc
2024/05/09	19 : 45	Business Wire	Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent	NYSE:MRK	Merck and Co Inc
2024/05/08	19 : 45	Business Wire	Merck to Participate in the Bank of America Securities 2024 Healthcare Conference	NYSE:MRK	Merck and Co Inc
2024/05/07	05 : 29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/01	20 : 15	Business Wire	Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	NYSE:MRK	Merck and Co Inc
2024/04/29	22 : 00	Business Wire	Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults	NYSE:MRK	Merck and Co Inc
2024/04/26	05 : 40	IH Market News	U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower	NYSE:MRK	Merck and Co Inc
2024/04/25	22 : 09	IH Market News	Futures Pointing To Sharply Lower Open On Wall Street	NYSE:MRK	Merck and Co Inc
2024/04/25	20 : 52	IH Market News	Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings	NYSE:MRK	Merck and Co Inc

Showing the most relevant articles for your search:NYSE:MRK

1 2 3 4 5 6 7 8 9 10 次へ >>

Avon Protection

First Oak Brook Bancshares

Telephone and Data Systems

Tricon Residential

Mobile TeleSystems Publi...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約